343.60

8.39% 26.60

After Hours: 343.60

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $343.60, with a volume of 703.32K. It is up +8.39% in the last 24 hours and up +16.89% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Previous Close:

$317.00

Open:

$325.95

24h Volume:

703.32K

Relative Volume:

1.52

Market Cap:

$9.57B

Revenue:

$7.46M

Net Income/Loss:

$-303.27M

P/E Ratio:

-25.51

EPS:

-13.4668

Net Cash Flow:

$-249.12M

1W Performance:

+12.03%

1M Performance:

+16.89%

6M Performance:

+554.23%

1Y Performance:

+1,055%

1-Day Range:

$325.95

$352.78

1-Week Range:

$311.01

$352.78

52-Week Range:

$28.79

$356.00

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1110)

Industry

Biotechnology (622)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

10,998

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	343.60	8.80B	7.46M	-303.27M	-249.12M	-13.47
VRTX Vertex Pharmaceuticals Inc	444.28	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	755.51	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	828.35	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	339.41	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	310.00	34.37B	5.36B	287.73M	924.18M	2.5229

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Strong Buy
Feb-24-26	Initiated	Wolfe Research	Outperform
Feb-02-26	Initiated	Wells Fargo	Equal Weight
Dec-15-25	Reiterated	Oppenheimer	Outperform
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

02:02 AM

Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga

02:02 AM

12:37 PM

Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com Canada

12:37 PM

12:31 PM

Jefferies reiterates Praxis Precision Medicines stock rating on FDA review By Investing.com - Investing.com Australia

12:31 PM

11:44 AM

PRAX Reiterated by Needham -- Price Target Maintained at $510 - GuruFocus

11:44 AM

08:18 AM

Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ) - Seeking Alpha

08:18 AM

07:41 AM

Praxis Precision Medicines Announces FDA Acceptance of NDA for Ulixacaltamide HCl for Essential Tremor Treatment, Target Action Date Set for January 29, 2027 - Quiver Quantitative

07:41 AM

07:40 AM

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor - Bitget

07:40 AM

07:30 AM

FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan

07:30 AM

02:54 AM

(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

02:54 AM

01:08 AM

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - National Today

01:08 AM

Apr 13, 2026

7 million Americans with essential tremor see a first positive Phase 3 program - Stock Titan

Apr 13, 2026

Apr 10, 2026

Raymond James Initiates Praxis Precision Medicines at Strong Buy With $815 Price Target - marketscreener.com

Apr 10, 2026

Apr 09, 2026

Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy - Investing.com

Apr 09, 2026

A Look At Praxis Precision Medicines (PRAX) Valuation After Positive Elsunersen Seizure Reduction Data - simplywall.st

Apr 09, 2026

Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN

Apr 09, 2026

Apr 08, 2026

PRAX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Apr 08, 2026

Apr 07, 2026

Wolfe Research Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $500 - Moomoo

Apr 07, 2026

A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $500 to $1,245 - Moomoo

Apr 07, 2026

Praxis Adds To Neuroscience Momentum With Epilepsy Trial Success - Citeline News & Insights

Apr 07, 2026

H.C. Wainwright reiterates Praxis Precision stock rating on trial data By Investing.com - Investing.com Canada

Apr 07, 2026

H.C. Wainwright reiterates Praxis Precision stock rating on trial data - Investing.com

Apr 07, 2026

HC Wainwright Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat

Apr 07, 2026

HC Wainwright & Co. Reiterates Buy Rating for PRAX with $1245 Ta - GuruFocus

Apr 07, 2026

Praxis Precision Medicines Announces Positive EMBRAVE Part A Trial Results for Elsunersen in Pediatric SCN2A Epileptic Encephalopathy - Minichart

Apr 07, 2026

Apr 06, 2026

Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $510 - moomoo.com

Apr 06, 2026

Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine - Investing.com Australia

Apr 06, 2026

Praxis reports positive elsunersen trial in pediatric epilepsies - TipRanks

Apr 06, 2026

Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine By Investing.com - Investing.com South Africa

Apr 06, 2026

Praxis Precision reports positive Phase 1/2 elsunersen results; FDA sets PDUFA for relutrigine - TradingView — Track All Markets

Apr 06, 2026

Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine - Stock Titan

Apr 06, 2026

Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential (PRAX) - Seeking Alpha

Apr 06, 2026

PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PR - GuruFocus

Apr 06, 2026

Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN

Apr 06, 2026

PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PRAX Stock News - gurufocus.com

Apr 06, 2026

BTIG Research Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - marketbeat.com

Apr 06, 2026

Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In TrialPraxis Precision Medicine (NAS - Benzinga

Apr 06, 2026

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - Investing News Network

Apr 06, 2026

Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy - TradingView — Track All Markets

Apr 06, 2026

In a nine-patient Praxis trial, children had 77% fewer seizures - Stock Titan

Apr 06, 2026

Apr 05, 2026

A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance

Apr 05, 2026

Aberdeen Group plc Takes $39.79 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Apr 05, 2026

Apr 04, 2026

PRAX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

SG Americas Securities LLC Cuts Position in Praxis Precision Medicines, Inc. $PRAX - marketbeat.com

Apr 04, 2026

Apr 03, 2026

(PRAX) Risk Channels and Responsive Allocation - Stock Traders Daily

Apr 03, 2026

Apr 02, 2026